CVS Health Corporation $CVS Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its holdings in CVS Health Corporation (NYSE:CVS) by 815.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,663,111 shares of the pharmacy operator’s stock after acquiring an additional 2,372,121 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.21% of CVS Health worth $183,701,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Cantor Fitzgerald Investment Advisors L.P. raised its stake in shares of CVS Health by 1.6% during the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock worth $28,264,000 after buying an additional 6,615 shares during the last quarter. USA Financial Formulas acquired a new position in shares of CVS Health during the 2nd quarter worth $1,429,000. First Pacific Financial raised its stake in shares of CVS Health by 1,310.7% during the 2nd quarter. First Pacific Financial now owns 2,116 shares of the pharmacy operator’s stock worth $146,000 after buying an additional 1,966 shares during the last quarter. Forza Wealth Management LLC raised its stake in shares of CVS Health by 5.5% during the 2nd quarter. Forza Wealth Management LLC now owns 8,989 shares of the pharmacy operator’s stock worth $620,000 after buying an additional 465 shares during the last quarter. Finally, LBP AM SA raised its stake in shares of CVS Health by 70.1% during the 2nd quarter. LBP AM SA now owns 238,759 shares of the pharmacy operator’s stock worth $16,470,000 after buying an additional 98,429 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 1.9%

CVS opened at $76.84 on Thursday. The stock has a market capitalization of $97.46 billion, a price-to-earnings ratio of 21.46, a price-to-earnings-growth ratio of 0.83 and a beta of 0.60. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $77.54. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The business has a 50-day moving average of $70.00 and a two-hundred day moving average of $67.19.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. During the same period last year, the company earned $1.83 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.22% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CVS shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $78.00 price target on shares of CVS Health in a research note on Tuesday, August 26th. Wolfe Research lifted their price target on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Sunday, September 21st. Zacks Research cut CVS Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Finally, Jefferies Financial Group lifted their price objective on CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 30th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.25.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.